literature

HIV mutation literature information.

Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.

PMID: 19537723 2009 Journal of chemical information and modeling

Abstract: Interestingly, in atazanavir complexes, in the presence of the L76V substitution, the drug revealed a more productive binding affinity, in agreement with hypersusceptibility data.

Combating HIV resistance - focus on darunavir.

PMID: 19209258 2008 Therapeutics and clinical risk management

Abstract: Darunavir resistance-associated mutations have been defined as V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V, and L89V.

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.

PMID: 18765410 2008 The Journal of antimicrobial chemotherapy

Abstract: The I437T/V mutation in gag and the L76V mutation in the protease were associated with a lower risk of selecting darunavir resistance mutations.

Abstract: There was an association between the presence of the mutation A431V in the gag sequence and the selection of the L76V mutation in the protease sequence in the latest available rebound.

Abstract: Virus with L76V in protease or I437T/V in gag may be already resistant to darunavir and, therefore, no additional resistance mutations need to be selected.

Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease.

PMID: 18097236 2008 AIDS (London, England)

Abstract: Besides I47A, mutation L76V at the HIV protease gene has recently been proposed to cause lopinavir resistance.

Abstract: Therefore, L76V does not appear to be a primary lopinavir resistance change when the drug is used in combination therapy.

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.

PMID: 18039922 2008 Antimicrobial agents and chemotherapy

Abstract: By contrast, L76V, a known DRV resistance mutation, was found to decrease the risk of selection of another DRV resistance mutation.

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

PMID: 17646201 2007 The Journal of antimicrobial chemotherapy

Abstract: The prevalence of major darunavir resistance mutations was I50V 2.1%, I54M 1.3%, L76V 2.7% and I84V 14.5%.

HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

PMID: 17500586 2007 PLoS computational biology

Figure: Includes the 22 mutations obtained from the mutation pairs with the highest positive association (Table 1) in bold, and 13 additional clinically relevant protease inhibitor resistance mutations (L10F, V32I, L33F, I47V, I50V/L, F53L, I54L/M, Q58E, L76V, V82T, and N88S).

Discussion: Protease covariation was dominated by the clustering of nelfinavir-associated mutations (D30N and N88D), two main groups of PI-resistance mutations

Browser Board

Co-occurred Entities

Filtrator